The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s ...

Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

According to deal terms announced Tuesday, Lilly is licensing Alchemab’s ATLX-1282, an antibody that the companies say brings a first-in-class approach to ALS and other neurodegenerative diseases.